Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ECC4703

Phase 2Small molecule

ECC4703 is one of 34 small molecule programs targeting Hepatitis. It is currently in Phase 2.

3

Indications

4

Total Trials

3

Active Trials

33

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Adult ObesityActive, not recruiting

Metabolic Dysfunction-Associated SteatohepatitisRecruiting

HepatitisPhase 2

Active, not recruiting

Adult ObesityPhase 2

Active, not recruiting

Metabolic Dysfunction-Associated SteatohepatitisPhase 2

Recruiting

Competition

Competitive Landscape

237 competitors in Hepatitis

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Crestor

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

PEG-Intron

Hepatitis B Vaccine

Cervarix

Cenicriviroc

TTobira Therapeutics, Inc.

Coenzyme Q10

MMclean Hospital

Recombinant Hepatitis B Vaccine

N-Acetylcysteine (NAC) Treatment

TThe First Affiliated Hospital of Soochow University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Adult Obesity

NCT07505303

Q3 2027

Phase 2Recruiting

Metabolic Dysfunction-Associated Steatohepatitis

NCT07288138

Clinical

Trials by Indication[1]

Adult1 trial

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

Recruiting·EEccogene·Phase 1·NCT07334080·72 enrolled

Metabolic Dysfunction-associated Steatohepatitis1 trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a THRβ Agonist (ECC4703), an SSAO Inhibitor (ECC0509), and Their Combination in Adults With Presumed MASH

Recruiting·EEccogene·Phase 2·NCT07288138·160 enrolled

Adult Obesity1 trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity

Active, not recruiting·EEccogene·Phase 2·NCT07505303·151 enrolled

Unspecified1 trial

FTIH of ECC4703 in Healthy Volunteers

Completed·EEccogene·Phase 1·NCT05552274·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ECC4703. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ECC4703 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ECC4703. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eccogene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEccogene

Related News